Anti‐PD1 monoclonal antibodies vs chemotherapy alone
Toxicity (≥ G3) · people with cutaneous melanoma
1 finding from 1 review
- 0.55 [0.31, 0.97]1360 participantsLow
Findings
What do systematic reviews say?
25 questions · 29 findings · 2 reviews
No studies found 1 · 3.4%GRADE not reported 0 · 0%Very low 1 · 3.4%Low 6 · 20.7%Moderate 13 · 44.8%High 8 · 27.6%
Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone
Progression‐free survival · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
- HR 0.76 [0.63, 0.92]502 participantsModerate
Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone
Tumour response · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).
1 finding from 1 review
- RR 1.28 [0.92, 1.77]1157 participantsModerate
Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
- RR 1.69 [1.19, 2.42]1142 participantsModerate
Anti‐CTLA4 monoclonal antibodies plus chemotherapy vs chemotherapy alone
Overall survival† · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in overall survival† compared with chemotherapy (low certainty).
1 finding from 1 review
- HR 0.81 [0.65, 1.01]1157 participantsLow